Paul C. Hendrie

4.0k total citations · 1 hit paper
80 papers, 1.7k citations indexed

About

Paul C. Hendrie is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Paul C. Hendrie has authored 80 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hematology, 29 papers in Molecular Biology and 24 papers in Oncology. Recurrent topics in Paul C. Hendrie's work include Acute Myeloid Leukemia Research (43 papers), Acute Lymphoblastic Leukemia research (17 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Paul C. Hendrie is often cited by papers focused on Acute Myeloid Leukemia Research (43 papers), Acute Lymphoblastic Leukemia research (17 papers) and Chronic Myeloid Leukemia Treatments (12 papers). Paul C. Hendrie collaborates with scholars based in United States, South Africa and Spain. Paul C. Hendrie's co-authors include Keisuke Miyazawa, David W. Russell, Hal E. Broxmeyer, Elihu H. Estey, Charlie Mantel, H E Broxmeyer, Steven A. Pergam, F. Marc Stewart, Pamela S. Becker and Tracy Wong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Paul C. Hendrie

77 papers receiving 1.7k citations

Hit Papers

Managing Cancer Care During the COVID-19 Pandemic: Agilit... 2020 2026 2022 2024 2020 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal
    2020 367 citations Paul C. Hendrie, F. Marc Stewart et al. Journal of the National Comprehensive Cancer Network profile →

Peers

Paul C. Hendrie
Gunjan L. Shah United States
Der‐Cherng Liang Taiwan
Aaron S. Rosenberg United States
Pamela J. Atherton United States
Neil A. Accortt United States
Kenneth B. Hymes United States
Leona Holmberg United States
Y. M. Dennis Lo Hong Kong
Koichiro Yuji Japan
Alfred Ian Lee United States
Gunjan L. Shah United States
Paul C. Hendrie
Citations per year, relative to Paul C. Hendrie Paul C. Hendrie (= 1×) peers Gunjan L. Shah

Countries citing papers authored by Paul C. Hendrie

Since Specialization
Citations

This map shows the geographic impact of Paul C. Hendrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul C. Hendrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul C. Hendrie more than expected).

Fields of papers citing papers by Paul C. Hendrie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul C. Hendrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul C. Hendrie. The network helps show where Paul C. Hendrie may publish in the future.

Co-authorship network of co-authors of Paul C. Hendrie

This figure shows the co-authorship network connecting the top 25 collaborators of Paul C. Hendrie. A scholar is included among the top collaborators of Paul C. Hendrie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul C. Hendrie. Paul C. Hendrie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Appelbaum, Jacob, Kathryn Russell, Xueyan Chen, et al.. (2024). Hematopoietic stem cell transplant for adults with mixed phenotypic acute leukemia.. Journal of Clinical Oncology. 42(16_suppl). 6517–6517.
2.
Othus, Megan, Anna B. Halpern, Jacob Appelbaum, et al.. (2023). Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents. Leukemia & lymphoma. 64(5). 990–996. 1 indexed citations
3.
Cassaday, Ryan D., Olga Sala‐Torra, Philip A. Stevenson, et al.. (2023). Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia. Leukemia & lymphoma. 64(5). 927–937. 4 indexed citations
4.
Othus, Megan, Mohamed L. Sorror, Anna B. Halpern, et al.. (2022). Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia. 37(1). 231–234. 4 indexed citations
5.
Halpern, Anna B., Megan Othus, Nicholas P. Howard, et al.. (2021). Comparative analysis of infectious complications with outpatient vs. inpatient care for adults with high-risk myeloid neoplasm receiving intensive induction chemotherapy. Leukemia & lymphoma. 63(1). 142–151. 2 indexed citations
6.
Starkebaum, Gordon & Paul C. Hendrie. (2020). Erdheim–Chester disease. Best Practice & Research Clinical Rheumatology. 34(4). 101510–101510. 29 indexed citations
7.
Halpern, Anna B., Megan Othus, Emily M. Huebner, et al.. (2018). Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 32(11). 2352–2362. 34 indexed citations
8.
Zhou, Yi, Brent L. Wood, Roland B. Walter, et al.. (2017). Is there a need for morphologic exam to detect relapse in AML if multi-parameter flow cytometry is employed?. Leukemia. 31(11). 2536–2537. 6 indexed citations
9.
Chamberlain, Marc C., et al.. (2017). Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy. Clinical Lymphoma Myeloma & Leukemia. 17(4). 225–230. 18 indexed citations
10.
11.
Martin, Daniel B., et al.. (2015). Development of a Hematology/Oncology ICD-10 Documentation Job Aid. Journal of the National Comprehensive Cancer Network. 13(4). 435–440. 3 indexed citations
12.
Hendrie, Paul C., et al.. (2015). Safe Implementation of Computerized Provider Order Entry for Adult Oncology. Applied Clinical Informatics. 6(4). 638–649. 19 indexed citations
13.
14.
Becker, Pamela S., Hagop M. Kantarjian, Frederick R. Appelbaum, et al.. (2011). Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia. British Journal of Haematology. 155(2). 182–189. 64 indexed citations
15.
Hendrie, Paul C. & David W. Russell. (2005). Gene Targeting with Viral Vectors. Molecular Therapy. 12(1). 9–17. 93 indexed citations
16.
Broxmeyer, H E, Scott Cooper, Nancy Hague, et al.. (1995). Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Annals of Hematology. 71(5). 235–246. 58 indexed citations
17.
Broxmeyer, H E, Stephanie Cooper, Nancy Hague, et al.. (1995). Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. Annals of Hematology. 71(5). 235–246. 9 indexed citations
18.
Hendrie, Paul C. & Hal E. Broxmeyer. (1994). Myeloid cell proliferation stimulated by steel factor is pertussis toxin sensitive and enhanced by cholera toxin. International Journal of Immunopharmacology. 16(7). 547–560. 6 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gunjan L. Shah Breakdown of academic impact, for papers by Der‐Cherng Liang Breakdown of academic impact, for papers by Aaron S. Rosenberg Breakdown of academic impact, for papers by Pamela J. Atherton Breakdown of academic impact, for papers by Neil A. Accortt Breakdown of academic impact, for papers by Kenneth B. Hymes Breakdown of academic impact, for papers by Leona Holmberg Breakdown of academic impact, for papers by Y. M. Dennis Lo Breakdown of academic impact, for papers by Koichiro Yuji Breakdown of academic impact, for papers by Alfred Ian Lee
Rankless by CCL
2026